You are here : Home > Funding & TTO > Europe > MICROB-PREDICT

Europe | European & international partnerships | Metabolomics | Diseases | Diagnosis


The pan-European research project MICROB-PREDICT aims to better understand the role of the human microbiome in the pathogenesis and evolution of cirrhosis and to imagine future personalized therapeutic strategies and diagnostic tools.

H2020 funding : RIA (Research and Innovation Actions)


Published on 3 February 2019


Every year, 1.2 million people worldwide die from complications of liver cirrhosis (decompensation, acute or chronic liver failure). The main causes of the disease are alcoholism and viral infections (hepatitis), with certain factors such as diabetes and obesity worsening the prognosis. Among the recent advances in the understanding of the disease, the role of the intestinal microbiota (formerly known as gut flora) in the pathogenesis and progression of the disease is of great interest. There are quantitative and qualitative differences in its composition between people with cirrhosis and healthy people, differences that are notably linked to the migration of certain microorganisms from or to other microbiota in the body (salivary microbiota, circulatory microbiota...). The study of the microbiota, or rather the microbiome, should therefore make it possible, on the one hand, to predict and prevent the occurrence and/or aggravation of cirrhosis and, on the other hand, to propose adapted and personalized therapeutic solutions. 

This is the challenge taken up by the MICROB-PREDICT consortium, funded by the European Union for six years. This pan-European research project will integrate data from some 10,000 patients, previously collected in other large-scale studies, constituting a database of more than 100,000 data points, including stool, blood, saliva, mucous membrane and urine samples taken throughout the course of the disease. The consortium is particularly interested in identifying biomarkers of different stages of the disease and exploiting them to develop tests for use by physicians or patients, such as emergency diagnostic tests (Point Of Care (POC)) tests. 

Project duration
6 years
15 millions €

​Number of partners

Starting date
January 01, 2019


Contact Joliot Institute: Christophe Junot (


H2020 AGReeMENT id: 825694

©MICROB-PREDICT consortium